Abstract
Most antiresorptive agents induce a profound decrease in bone turnover with maximal suppression of bone resorption markers within 1–6 months of treatment, and a somewhat delayed decrease in bone formation markers. The magnitude of suppression in bone markers appears to depend on the dose and potency of the drug chosen as well as the marker used. This chapter reviews the current knowledge on the use of bone turnover markers in monitoring the effects of antiresorptive treatment in osteoporosis. It discusses the effects of pretreatment bone turnover on therapeutic outcomes, and then looks at the role of bone turnover markers in monitoring antiresorptive therapies, paying particular attention to the associations between changes in bone turnover and changes in bone mineral density and fracture risk. This chapter also reviews the interpretation of changes in bone turnover markers based upon the concept of biologic mechanism and random error.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
